These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 37013346)
1. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance. Sung HY; Han J; Chae YJ; Ju W; Lee Kang J; Park AK; Ahn JH BMB Rep; 2023 Jun; 56(6):347-352. PubMed ID: 37013346 [TBL] [Abstract][Full Text] [Related]
2. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249 [TBL] [Abstract][Full Text] [Related]
3. The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance. Manzoor HB; Asare-Werehene M; Pereira SD; Satyamoorthy K; Tsang BK J Ovarian Res; 2024 Jan; 17(1):15. PubMed ID: 38216951 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer. Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252 [TBL] [Abstract][Full Text] [Related]
6. Investigation of role of CpG methylation in some epithelial mesenchymal transition gene in a chemoresistant ovarian cancer cell line. Alghamian Y; Soukkarieh C; Abbady AQ; Murad H Sci Rep; 2022 May; 12(1):7494. PubMed ID: 35523936 [TBL] [Abstract][Full Text] [Related]
7. The effect of sodium butyrate and cisplatin on expression of EMT markers. Mrkvicova A; Chmelarova M; Peterova E; Havelek R; Baranova I; Kazimirova P; Rudolf E; Rezacova M PLoS One; 2019; 14(1):e0210889. PubMed ID: 30653577 [TBL] [Abstract][Full Text] [Related]
8. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Chen B; Chen J; House MG; Cullen KJ; Nephew KP; Guo Z Mol Cancer Res; 2012 Mar; 10(3):305-15. PubMed ID: 22246235 [TBL] [Abstract][Full Text] [Related]
9. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer. Sung HY; Yang SD; Park AK; Ju W; Ahn JH Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492 [TBL] [Abstract][Full Text] [Related]
10. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312 [TBL] [Abstract][Full Text] [Related]
11. An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cells. Vera O; Rodriguez-Antolin C; de Castro J; Karreth FA; Sellers TA; Ibanez de Caceres I Epigenetics; 2018; 13(3):251-263. PubMed ID: 29436261 [TBL] [Abstract][Full Text] [Related]
12. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. Dai W; Teodoridis JM; Graham J; Zeller C; Huang TH; Yan P; Vass JK; Brown R; Paul J BMC Bioinformatics; 2008 Aug; 9():337. PubMed ID: 18691414 [TBL] [Abstract][Full Text] [Related]
13. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140 [TBL] [Abstract][Full Text] [Related]
14. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814 [TBL] [Abstract][Full Text] [Related]
15. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Shen L; Kondo Y; Ahmed S; Boumber Y; Konishi K; Guo Y; Chen X; Vilaythong JN; Issa JP Cancer Res; 2007 Dec; 67(23):11335-43. PubMed ID: 18056460 [TBL] [Abstract][Full Text] [Related]
16. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Chen HY; Shao CJ; Chen FR; Kwan AL; Chen ZP Int J Cancer; 2010 Apr; 126(8):1944-1954. PubMed ID: 19626585 [TBL] [Abstract][Full Text] [Related]
17. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Strathdee G; MacKean MJ; Illand M; Brown R Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053 [TBL] [Abstract][Full Text] [Related]
18. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP]. Meng CF; Dai DQ; Guo KJ Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988 [TBL] [Abstract][Full Text] [Related]
19. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589 [TBL] [Abstract][Full Text] [Related]
20. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer. Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]